High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia

Recurrent mutations are implicated in the prognosis of myeloid malignancies and are likely to be incorporated into the next WHO classification. We evaluated a pooling approach for cost-effective targeted sequencing in combination with a clinically accredited method for validating point mutations,